Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating

About this episode

Daniel Chen discusses objective-driven protein engineering and the SYNTHBODY platform for drug discovery.

May 12, 2026 | When it comes to drug discovery, either you find a rare, clean target and everything clicks, or you spend a decade chasing biology that refuses to cooperate. Daniel Chen, M.D., Ph.D., founder and CEO of Synthetic Design Lab, makes the case for a different playbook: objective-driven protein engineering, where we start with the outcome and design biologics that can execute it with built-in logic. With host Andrew Bradbury, Chen unpacks the SYNTHBODY platform and what “multi-tier ...

People in this episode

Host: Andrew Bradbury

Guest: Daniel Chen

Topics covered

• drug discovery
• protein engineering
• biologics
• SYNTHBODY platform
• multi-target drugs
• logic gating

Keywords

• drug discovery
• protein engineering
• biologics
• multi-target drugs
• logic gating
• SYNTHBODY

Mentioned in this episode

Organizations: Synthetic Design Lab

More episodes of The Chain: Protein Engineering Podcast

• Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D · June 9, 2026 · 54 min
• Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design · April 15, 2026 · 39 min
• Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement · March 17, 2026 · 59 min
• Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies? · February 10, 2026 · 49 min
• Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research · January 13, 2026 · 44 min
• Episode: 80 - Vibha Jawa Discusses the Impact of Biologic Molecules and the Future of Immunogenicity · December 9, 2025 · 27 min